There are a number of reasons I believe this is a great...

There are a number of reasons I believe this is a great investment, so I will spell them out here.

Firstly, let's consider that this is a newly listed IPO, which trades very different to a spec stock in a trading pattern. This stock has a super tight register, consisting of one of the best T20's you'll find in a new float:

Jason Loveridge (Chairman & largest shareholder) - $500K invested @ IPO
Andrew Forrest (Former broker & very connected) - $2M invested @ IPO
David McAuliffe (Director) - $50K invested @ IPO
Kim Hogan (Very experienced Biotech broker) - $310K invested @ IPO
Tom Henderson (Very experienced Biotech broker) - $310K invested @ IPO
Tony Grist (Former broker & very connected) - $310K invested @ IPO
Jason Peterson (Very experienced broker) - $500K invested @ IPO

Forrest Capital have done this before, they have the right investors & that goes a long way to getting the SP moving in the right direction when launching a new float.

Then there are the fundamentals of the business:

Alexandra Sinclair has been working on these solutions for the past 10yrs, she is one of the worlds leading experts on the issues IXC is looking to solve. Repurposing drugs that are well documented with excellent safety records is well known for increasing shareholder value & the company is currently more than 50% through its current phase II trials for its IIH solution.

Then there is the potential for news surrounding additional use cases, the biotech sector doing very well with some excellent M&A activity in the space.

Basically these IPO shares were difficult to get, so investors will not part with them easily. This feels a lot like A3D back in 2016.

Good luck to everyone here & well done to all holders